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Abstract
 
Although Toll-like receptors (TLRs) are critical mediators of the immune response to pathogens,
the influence of polymorphisms in this gene family on human susceptibility to infection is
poorly understood. We demonstrated recently that TLR5 recognizes flagellin, a potent inflam-
matory stimulus present in the flagellar structure of many bacteria. Here, we show that a common
stop codon polymorphism in the ligand-binding domain of TLR5 (TLR5
 
392STOP
 
) is unable to
mediate flagellin signaling, acts in a dominant fashion, and is associated with susceptibility to
pneumonia caused by 
 
Legionella pneumophila
 
, a flagellated bacterium. We also show that flagellin is
a principal stimulant of proinflammatory cytokine production in lung epithelial cells. To-
gether, these observations suggest that TLR5
 
392STOP
 
 increases human susceptibility to infection
through an unusual dominant mechanism that compromises TLR5’s essential role as a regulator
of the lung epithelial innate immune response.
Key words: inﬂammation • immunity • genetic predisposition to disease • genetic markers • 
bacterial infections
 
Introduction
 
Pneumonia is the sixth leading cause of death in the United
States and the most common cause of death due to infectious
disease (1). Despite the seriousness of pneumonia, very little
is known about genetic factors that predispose individuals
to acquire lower respiratory tract infections. Recent advances
in innate immunity and genetics are opening avenues to
examine the immunologic and genetic factors that predispose
individuals to acquire common infections such as pneumonia
(2). The innate immune system enables the host to differ-
entiate itself from invading microbes, discriminate among
pathogens, and initiate a cascade of inflammatory molecules
that influence formation of the acquired immune response
as well as host survival. Toll-like receptors (TLRs) constitute a
family of transmembrane proteins that differentially recognize
pathogen-associated molecular patterns (PAMPs) through
an extracellular domain and initiate inflammatory signaling
pathways through an intracellular domain (3–6). Due to
the central role of TLRs in the innate immune response,
genetic variation in this gene family is predicted to alter
susceptibility to infections in a PAMP-specific manner based
on the ligand recognition of the individual TLR. Although
initial papers have supported this hypothesis for TLR4, the
 
Address correspondence to Thomas R. Hawn, Institute for Systems Biol-
ogy, 1441 N. 34th St., Seattle, WA 98103. Phone: (206) 732-1377; Fax:
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Abbreviations used in this paper:
 
 CHO, Chinese hamster ovary; CI, con-
fidence interval; ELAM, endothelial leukocyte adhesion molecule; LD,
Legionnaires’ disease; OR, odds ratio; PAMP, pathogen-associated
molecular pattern; SNP, single nucleotide polymorphism; TLR, Toll-
like receptor.T
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degree to which other TLRs affect susceptibility to infections
is unknown (7–11).
We demonstrated recently that TLR5 recognizes the
flagellin protein, a potent inflammatory stimulus present in
the flagellar structure of many bacteria (12, 13). Herein, we
provide the first evidence that TLR5 influences human
susceptibility to infection as well as describe an important
role for TLR5 in the innate immune response of the lung
epithelium.
 
Materials and Methods
 
Materials. 
 
RPMI 1640 medium, 
 
l
 
-glutamine, penicillin, and
streptomycin were obtained from Life Technologies, DMEM
was obtained from JRH Biosciences, and Ham’s F12 was ob-
tained from BioWhittaker. Ultrapure LPS was from 
 
Salmonella
minnesota
 
 R595 (List Biological Labs, Inc.). Flagellin was purified
from 
 
Salmonella typhimurium
 
 as described previously from strain
TH4778, which is fljB
 
 
 
/fliC
 
 
 
 (a gift from K. Hughes, University
of Washington, Seattle, WA; references 12, 14).
 
Cells, Mice, and Bacteria. 
 
Chinese hamster ovary (CHO) cells
(CHO-K1), A549 cells, HEK 293 cells, and Calu-3 cells were
grown according to American Type Culture Collection recom-
mendations. PBMCs were isolated from 50 ml of blood from in-
dividuals with a Ficoll gradient separation. MyD88
 
 
 
/
 
 
 
 and
TLR4
 
 
 
/
 
 
 
 mice (a gift from S. Akira, Research Institute for Mi-
crobial Diseases, Osaka University, Japan) were derived on a
129SvJ 
 
 
 
 C57Bl/6 background, backcrossed for six generations
to C57Bl/6, and used for experiments along with littermate con-
trols (15, 16). Bone marrow was harvested from these mice and
grown in RPMI 1640 supplemented with 10% heat-inactivated
FCS (Hyclone Laboratories), 20% L cell–conditioned media, 100
U/ml penicillin, 100 
 
 
 
g/ml streptomycin, and 2 mM 
 
l
 
-gluta-
mine. Bone marrow–derived macrophages were used after 4–10 d
of culture. The University of Washington and Institute for Sys-
tems Biology’s Institutional Animal Care and Use Committees
approved all animal protocols. 
 
L. pneumophila
 
 Corby (serogroup 1)
and 
 
L. pneumophila
 
 Corby FlaA
 
 
 
 were gifts from K. Heuner
(University of Wurzburg, Wurzburg, Germany), and the JR32
strain was a gift from H. Shuman (Columbia University, New
York, NY; references 17, 18). The Bovenkarspel strain was a gift
from R. van Ketel (Academic Medical Center, Amsterdam,
Netherlands). Knoxville-1 and Philadelphia-1 strains were ob-
tained from American Type Culture Collection. For stimulation
assays, bacteria were grown on buffered charcoal yeast extract–
agar at 35
 
 
 
C (with kanamycin selection for the FlaA
 
 
 
 mutant),
resuspended in PBS, and heat killed for 65
 
 
 
C for 15 min (17).
 
Human Subjects and Data Collection. 
 
Approval for human
study protocols was obtained from the human subjects review
boards at the University of Amsterdam Medical Center, the Uni-
versity of Washington Medical Center, and the Institute for Sys-
tems Biology. All participants gave written informed consent.
Genomic DNA was purified from peripheral blood leukocytes
from 10 ml of blood. The first study group included 54 healthy
volunteers from the Seattle, WA area. Enrollment of the cases and
controls from the Legionnaires’ disease (LD) outbreak in the
Netherlands has been described previously (19–21). Of the 188
cases identified in the original investigation of the outbreak, 141
consented for the study. 18 individuals died and no DNA was
available for genotyping. 108 cases were available (93 definite LD,
15 probable LD) with both DNA and epidemiologic data for
analysis. Controls were drawn from the exhibitioners who
 
worked at the flower show and were at high risk for exposure to
 
Legionella pneumophila
 
. 1,616 controls were contacted by letter to
be in the analysis. The first 508 who completed the questionnaire
had blood drawn for genetic analysis.
 
Statistics. 
 
Univariate analysis was performed for categorical
variables with chi-square test, and for continuous variables using a
Student’s 
 
t
 
 test. Single nucleotide polymorphism (SNP) data were
analyzed using a recently developed methodology based on an es-
timating equation technique, the details of which have been de-
scribed previously (22, 23). The basic idea is to estimate the dis-
tribution of haplotypes from SNP genotype data, to correlate all
common haplotypes with LD phenotype with adjustment for de-
mographic variables, and to assess interactions of haplotypes with
exposure factors. The penetrance of paired haplotypes (H,h) and
exposure (E) to LD outcome (D 
 
  
 
1) is quantified via a logistic
regression model:
where unknown parameter 
 
 
 
 in the function G(H,h,
 
 
 
) quantifies
disease associations with haplotypes, 
 
 
 
 quantifies the disease asso-
ciation with exposure, and 
 
 
 
 in I(H,h,E,
 
 
 
) quantifies the disease
associations with the interaction of haplotypes and exposure. Esti-
mating regression parameters (
 
 
 
,
 
 
 
) is of primary interest because
their relevant statistics can be used to make scientific inferences.
The key challenge to the estimation is that the haplotype struc-
ture for many individuals is not observed (i.e., phases of SNP al-
leles are not observed).
 
Molecular Biology. 
 
SNP discovery and genotyping was per-
formed by PCR amplification of TLR5 from genomic DNA fol-
lowed by sequencing. To generate templates for sequencing, the
coding region of TLR5 was amplified from 25 ng of genomic
DNA in two fragments with Amplitaq DNA polymerase
(Applied Biosystems). Primers for fragment A were as follows:
T5-5, forward, 5
 
 
 
-GTATCTGCCAACAGCCACGTCTGTGG-
3
 
 
 
; and T5-23, reverse, 5
 
 
 
-GAGAATCTGGAGATGAGGTAC-
CCG-3
 
 
 
. Primers for fragment B were as follows: T5-3, forward,
5
 
 
 
-GCATACCCGATATCTTCTTGAGTGGC-3
 
 
 
; and T5-21,
reverse, 5
 
 
 
-CTGGAAACCTCTAAGGGCAGTTGC-3
 
 
 
. For geno-
typing by DdeI restriction digestion, a 276-bp PCR product was
first generated with primers T5-11, forward, 5
 
 
 
-GGTAGCCTA-
CATTGATTTGC-3
 
 
 
; and T5-23, digested with DdeI (New
England Biolabs, Inc.), and separated on a 1.8% agarose gel. For
functional studies, the coding region of TLR5 was amplified from
genomic DNA by PCR using Pfu Turbo polymerase (Stratagene)
and cloned into the pEF6/V5-His-TOPO vector (Invitrogen).
PCR primers for the full length gene included T5-10, forward,
5
 
 
 
-ATGGGAGACCACCTGGACCTTCTCC-3
 
 
 
; and T5-30,
reverse, 5
 
 
 
-GGAGATGGTTGCTACAGTTTGCAACGG-3
 
 
 
. PCR
primers for TLR5
 
392STOP
 
 were T5-10, forward; and T5-31, re-
verse, 5
 
 
 
-GAGATCCAAGGTCTGTAATTTTTCCAGG-3
 
 
 
. To
obtain the different polymorphic variants of TLR5, genomic
DNA was selected from individuals with the desired genotype.
The cloned variants of TLR5 were sequenced for verification
with Big Dye Terminator v3.0 and analyzed on a capillary se-
quencer (model ABI PRISM 3700; Applied Biosystems). Se-
quence was aligned and analyzed with the programs PHRED/
PHRAP and CONSED (24).
 
Transfections. 
 
CHO cells were transfected as described previ-
ously (12). HEK293 cells were transfected as described previously
in a 96-well plate format with calcium phosphate, using 5 
 
 
 
 10
 
4
 
cells per well with 8 ng of TLR5, 8 ng of pRL-TK, and 80 ng of
endothelial leukocyte adhesion molecule (ELAM)–luciferase per
Pr D 1 H,h,E = ()
1 1 exp α – G – H,h β (, ) γE – I – H,h,E δ (, ) () + {} , ⁄
=T
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well (25). For some experiments, HEK293 cells were alterna-
tively transfected with Polyfect (QIAGEN) according to the
manufacturer’s instructions with 5 
 
 
 
 10
 
4
 
 cells per well in a 96-
well plate with 175 ng TLR5, 8 ng pRL-TK, and 80 ng of
ELAM-luciferase per well. Stimulated cells were processed as de-
scribed previously (12).
 
Protein Analysis. 
 
For the immunoblot, cells were lysed with
1% Triton X-100/150 mM NaCl/10 mM Hepes, pH 8.0, or pas-
sive lysis buffer (Promega) with a cocktail of protease inhibitors
(Sigma-Aldrich). An immunoblot with proteins from cell lysates
was probed with an anti-V5 epitope antibody (Serotec) followed
by HRP-conjugated rabbit anti–mouse IgG (Zymed Laborato-
ries) and developed with chemiluminescent reagents (Roche).
Whole blood cytokine assays were prepared by diluting venous
blood 1:5 with RPMI 1640, plating in a 96-well dish, stimulating
for 18 h, and harvesting supernatants. For Calu-3 and A549 as-
says, cells were plated at a density of 2 
 
 
 
 10
 
4
 
 per well in a 96-well
dish, stimulated for 18 h, and supernatants were harvested. Cyto-
kine levels were determined with a sandwich ELISA technique
(Duoset; R&D Systems).
 
Results
 
TLR5 SNP Discovery. 
 
To discover novel SNPs with
disease association, we PCR amplified and sequenced the
TLR5 coding region in 40 healthy individuals. TLR5 is a
type I transmembrane protein with a 642–amino acid leu-
cine-rich extracellular domain, an 18-residue transmem-
brane domain, and a 198-residue cytoplasmic Toll homol-
ogy signaling domain. Four SNPs were detected in TLR5.
Most dramatic was a cytosine–thymidine transition at base
pair 1174 that changed the arginine at amino acid 392 to a
stop codon (Fig. 1 A, TLR5
 
392STOP
 
). This change is pre-
dicted to prematurely truncate TLR5 in the extracellular
domain and cause the loss of the transmembrane domain
and the entire signaling cytoplasmic tail. We verified this
polymorphism with a DdeI restriction enzyme digestion,
which selectively cut a 276-bp PCR product encompassing
the 1174T variant (Fig. 1 B). Two additional nonsynony-
mous SNPs (A1775G [amino acid N592S] and T1846C
[F616L]) alter residues in the ectodomain, whereas a fourth
synonymous SNP (A2523G [K841K]) was in the cytoplas-
mic tail. The frequency of subjects who possessed the stop
codon variant as heterozygotes (1174 CT) and homozy-
gotes (1174 TT) was 7.5 and 0%, respectively. The serine
variant at amino acid 592 and the leucine variant at 616
were present as heterozygote frequencies of 35.0 (1775
AG) and 45.0% (1846TC), and homozygote frequencies of
5.0 (1775 GG) and 15.0% (1846 CC), respectively. The
synonymous SNP at amino acid 841 (A2523G) was present
as a heterozygote frequency of 20.0% (2523 AG) and a ho-
mozygote frequency of 0% (2523 GG). Except for minor
deviations, the observed allelic frequencies of these four
SNPs were consistent with expected allelic frequencies un-
der the Hardy–Weinberg equilibrium.
cDNAs encoding the TLR5 polymorphisms were am-
plified by PCR and cloned into the pEF6-TOPO expres-
sion vector in frame with a COOH-terminal V5-epitope
tag. The full-length constructs were labeled TLR5
 
RNF
 
,
TLR5
 
RNL
 
, and TLR5
 
RSF
 
, using the single letter designa-
tions of the amino acids at the three polymorphic amino
acid positions (392, 592, and 616). When assessed by West-
ern blot, TLR5
 
RNF
 
, TLR5
 
RNL
 
, and TLR5
 
RSF
 
 protein ex-
pression levels were similar in transfected CHO cells (Fig. 1
C). TLR5
 
392STOP
 
 was expressed at higher levels in compar-
ison to the full-length versions and was detected as a dou-
blet band, which may be secondary to proteolysis or glyco-
sylation. Next, we examined whether TLR5
 
392STOP
 
 was
able to mediate flagellin signaling. We transfected CHO
cells with TLR5 variants along with an NF-
 
 
 
B firefly lu-
ciferase reporter plasmid (ELAM) and stimulated with puri-
fied 
 
S. typhimurium
 
 flagellin for 4 h (12). Flagellin induced
NF-
 
 
 
B activity in cells expressing the full length TLR5
(Fig. 1 D). In contrast, cells expressing TLR5
 
392STOP
 
 were
unable to respond to flagellin. Identical results were ob-
Figure 1. TLR5 polymorphisms and FliC signaling. (A) Sequence
chromatogram indicating a polymorphism at base pair 1174. Amino acids
are numbered for the respective protein depictions. The diagonal stripes
at amino acid 643–660 indicate the transmembrane domain. (B) DdeI
restriction digest to verify C1174T SNP. Lanes 1 and 2, genotype 1174
CC; lanes 3 and 4, genotype 1174 CT. Lanes 1 and 3, no DdeI; lanes 2
and 4, with DdeI. (C) Western immunoblot. CHO cells were transfected
with control vector (lane 1, pEF6 without insert), TLR5RNF (lane 2),
TLR5RNL (lane 3), TLR5RSF (lane 4), or TLR5392STOP (lane 5). Immuno-
blot probed with an anti-V5 antibody. (d and e) Luciferase assay in CHO
(D) and HEK293 (E) cells. Cells were transfected with pEF6 control ( ),
TLR5RNF ( ), or TLR5–392STOP ( ), an NF- B luciferase reporter, and
pRL-TK as a transfection control. (F) Luciferase assay in HEK293 cells
transfected with: pEF6 control ( ), TLR5RNF ( ), TLR5RNL ( ), or
TLR5RSF ( ). RLU, relative luciferase unit. Assays performed in triplicate
with standard deviations indicated. (D–F) Transfected cells were stimu-
lated for 4 h with S. typhimurium FliC at the indicated concentration be-
fore determining luminescence levels.T
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tained in HEK293 cells, demonstrating that the inability of
TLR5392STOP to mediate flagellin signaling was not cell spe-
cific (Fig. 1 E). Incubation with LPS at 100 ng/ml did not
induce any luciferase activity in TLR5-transfected CHO
cells and polymyxin B did not alter the results of the flagel-
lin stimulation (unpublished data). These controls demon-
strated that the TLR5-mediated NF- B response was
flagellin specific. In contrast to the results obtained with
TLR5392STOP, the other variants of TLR5 were fully func-
tional in mediating flagellin signaling. When introduced
into HEK293 cells, TLR5-RNL and TLR5-RSF were no
different from TLR5-RNF in mediating flagellin signaling
(Fig. 1 F). As seen in CHO cells, Western blot analysis re-
vealed similar levels of expression of the three variants in
HEK293 cells (Fig. 1 C, not depicted).
SNPs in TLR5 Are Associated with Susceptibility to LD.
Next, we examined whether these TLR5 SNPs were asso-
ciated with susceptibility to human infection in a PAMP-
specific manner. L. pneumophila, first described in 1976 as
the agent of LD, is a flagellated gram-negative bacteria that
causes anywhere from 1 to 30% of cases of community-
acquired pneumonia (26–30). We found that heat-killed L.
pneumophila (serogroup 1, Corby strain) induced NF- B
activity in TLR5-transfected CHO cells (Fig. 2 A). This
stimulatory activity was abolished in flagellin mutant strains
of L. pneumophila (FlaA  Corby strain; reference 17). In
addition, we found that several other strains of L. pneumo-
phila stimulated TLR5 activity, including the Bovenkarspel
strain, which caused a recent epidemic of LD at a flower
show in the Netherlands in 1999 (19). We also stimu-
lated bone marrow–derived macrophages from wild-type,
TLR4 / , and MyD88 /  mice with heat-killed L. pneu-
mophila. Although TNF-  and IL-6 levels were abolished
in MyD88 /  macrophages, there was no decrease in the
TLR4 /  cells in comparison to wild-type controls (Fig. 2,
B and C). In contrast, as a control, cytokine production
was abolished in both TLR4 /  and MyD88 /  macro-
phages stimulated with S. typhimurium LPS. These results
demonstrate that TLR4 is not involved in recognition of L.
pneumophila by murine macrophages.
To determine whether TLR5 is associated with suscepti-
bility to LD, we examined genotypes in a case-control co-
hort from the Bovenkarspel epidemic (19–21). Cases in-
cluded individuals with radiologically confirmed pneumonia
occurring during the epidemic time period around the West
Friese Flower Show in the town of Bovenkarspel in the
Netherlands. Controls were drawn from a pool of exhibi-
tioners who were likely to be exposed to the contaminated
water product that caused the epidemic. All of the cases and
controls were from the Netherlands and  95% of both
groups were Caucasian Dutch. To provide an additional
control for population admixture, 89 of the 508 controls
were matched to cases for their place of residence   25 km,
as well as age and sex. The baseline characteristics of the case
and control groups are shown in Table I. The mean age and
the prevalence of diabetes were statistically different be-
tween cases and controls. In addition, smoking appeared to
be marginally different between cases and controls. To for-
mally assess the associations of age, sex, diabetes, and smok-
ing status, our null hypothesis is that these variables do not
associate with LD when comparing cases and controls (odds
ratio [OR]   1), in contrast to an alternative hypothesis of
OR   1 or OR   1. A two-sided test was used for the
purpose of evaluating statistical significance. Next, we ad-
justed the analysis by logistic regression with covariates for
age (stratified into  40, 40–49, 50–60, and  60), gender,
diabetes status, and smoking status. In the adjusted analysis,
smoking status (OR   2.84; 95% confidence interval [CI]  
1.55–5.21; P   0.05) and age (OR in reference to 40–49
age group: OR   0.071 (age, 0–39); CI   0.01–0.57; P  
0.05; OR   2.30 (age, 50–60); CI   1.0–5.29; P   0.05;
and OR   21.80 (age,  60); CI   9.26–51.28; P   0.05)
had a significant association with LD. In contrast, gender
(OR   1.09; CI   0.62–1.91) and diabetes status were not
associated with LD (OR   1.43; CI   0.51–4.03).
Next, we determined the genotype and allele frequen-
cies of individuals for the three nonsynonymous TLR5
SNPs (Tables II and III). There was no significant depar-
ture from the Hardy–Weinberg equilibrium of the ob-
served and expected frequencies of cases or controls for
these SNPs. The 1174T (stop codon variant) and 1775G
alleles were both associated with susceptibility to LD. The
allele frequency of 1174T was 8.3% in the cases compared
with 5.0% in the entire control group and 4.5% in the
Figure 2. (A) L. pneumophila activates TLR5 through FliC. CHO cells
were stably transfected with an NF- B luciferase promoter and either a
control vector (pEF6, shaded bars) or TLR5RNF (white bars). Cells were
stimulated with S. typhimurium FliC at 10 ng/ml 1, S. minnesota LPS at
100 ng/ml 1, or heat-killed L. pneumophila (multiplicity of infection  
250:1). Strains of L. pneumophila are as follows: LpWT, wild-type Corby
strain; LpFlaA , Corby strain FliC mutant; Boven, Bovenkarspel; Phil,
Philadelphia; Knox, Knoxville. RLU, relative luciferase unit. (B and C) L.
pneumophila stimulates macrophages through MyD88, but not TLR4.
Macrophages were derived from mouse bone marrow and stimulated with
PBS (white bars), S. minnesota LPS at 10 ng ml 1 (shaded bars), or LpWT
(multiplicity of infection   100:1; black bar). After 16 h of stimulation,
supernatants were assayed by ELISA for TNF-  (B) or IL-6 (C). WT,
wild type. T4, TLR4 / . M88, MyD88 /  mouse strains. (A–C) Assays
performed in triplicate with standard deviations indicated. (A) Transfected
cells were stimulated for 4 h before determining luminescence levels.T
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matched control group. For the purpose of assessing ge-
netic association, our formal null hypothesis is that individ-
ual alleles or their haplotypes do not associate with case-
control status (i.e., OR   1). The alternative hypothesis is
that there is some association, with OR   1 or OR   1.
Two-sided testing was used again for evaluating statistical
significance. The OR for the association of allele 1174T
with developing LD was 1.75 (95% CI   1.00–3.05; P  
0.05) when compared with the entire control group. The
association of 1174T with LD is even more striking be-
cause this stop codon variant was almost exclusively present
as a heterozygote genotype, as there were only two ho-
mozygote individuals in the entire cohort (1174TT). The
presence of both homozygote stop codon individuals in the
Table I. Baseline Clinical Characteristics of Cases and Controls
Cases
n   108
All controls 
n   508
Matched controls
n   89
n (%)  n (%) OR (95% CI) P  n (%) OR (95% CI) P
Male 65 (60.2) 261 (52.4) 1.37 (0.90, 2.10) 0.14 53 (60.2) 1.00 (0.56, 1.77) 1.00
Smoking 47 (49.0) 172 (40.6)  1.41 (0.90, 2.19) 0.13 32 (42.7)  1.29 (0.70, 2.37) 0.41
History of
COPD 8 (7.8) 39 (7.8) 1.01 (0.46, 2.23) 0.98 4 (4.5) 1.81 0.39a
DM 10 (10.1) 14 (2.8) 3.92 (1.69, 9.09)  0.05 5 (5.6) 1.89 0.29a
Malignancy 4 (4.0) 12 (2.5) 1.64 0.50a 2 (2.3) 1.77 0.69a
Rheum 2 (2.0) 13 (2.6) 0.78 1.00a 4 (4.5) 0.44 0.43a
Mean   SD Mean   SD P Mean   SD P
Age 63.8   10.8 44.9   13.6  0.05b 54.6   11.2  0.05b
Prevalence of baseline demographic and clinical information is indicated. Statistics are reported for each control population in reference to the cases.
The odds ratios (OR) with 95% confidence intervals is indicated (CI). Chi-square test used to calculate two-sided significance values. Not all variables
were known in all patients.
aFor subgroups with small sample numbers, a Fisher’s exact test was used.
bMean ages compared with an independent sample t test.
%, number of patients tested for that variable; Rheum, rheumatologic disorder; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.
Table II. TLR5 SNP Genotype Frequencies in Cases and Controls
Cases
n   108
All controls
n   89
Matched controls
n   89
Total
n   616
Genotype
Amino
Acid n (freq) n (freq) n (freq) n (freq)
1174 CC  392RR  90 (0.833) 457 (0.905) 82 (0.921) 547 (0.892)
1174 CT  392R*  18 (0.167) 46 (0.091)  6 (0.067) 64 (0.104)
1174 TT  392* 0 (0) 2 (0.004) 1 (0.011) 2 (0.003)
1775 AA  592NN  72 (0.692)  383 (0.777)  71 (0.798)  455 (0.762)
1775 AG 592NS  28 (0.269) 106 (0.215) 18 (0.202)  134 (0.224)
1775 GG  592SS  4 (0.038) 4 (0.008) 0 (0) 8 (0.010)
1846 TT  616FF  28 (0.277) 126 (0.260) 21 (0.239) 154 (0.263)
1846 TC  616FL  49 (0.485)  252 (0.520) 53 (0.602)  301 (0.514)
1846 CC  616LL  24 (0.238) 107 (0.221) 14 (0.159) 131 (0.224)
TLR5 genotypes were determined in cases and controls. *, stop codon.T
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control group is likely due to the larger control sample size
(n   508) as compared with the cases (n   108). In addi-
tion, although the controls were selected for an increased
risk of contact with L. pneumophila, the actual exposure
dose of each individual is not known. The OR for the
comparison with the matched control group showed a sim-
ilar trend, but was not significant due to the small sample
size (OR   1.93; 95% CI   0.74–5.03). The OR for the
association of allele 1775G with LD was 1.60 (95% CI  
1.04–2.45; P   0.03) compared with the entire control
group and 1.83 (95% CI   1.02–3.28; P   0.04) for the
matched cohort. There was no association of SNP T1846C
with LD. To determine if coinheritance of 1174T and
1775G further increased the risk of pneumonia, we exam-
ined the association of TLR5 haplotypes with susceptibility
to LD (22, 23). However, no haplotypes containing both
1174T and 1775G were detected in either cases or controls
(Table III, labeled 11). In the analysis by haplotypes, the as-
sociation of 1174T-1775A (haplotype 10; OR   1.90; P  
0.03) and 1174C-1775G (haplotype 01; OR   1.68; P  
0.02) with susceptibility to LD was also present (23). Next,
we considered whether any variables might be confounders
in the analysis, an unlikely possibility given that there is no
overt biologic relationship of TLR5 to any of the variables
in Table I. We repeated the analysis with an adjustment for
sex and age (stratified into  40, 40–49, 50–60, and  60)
and found a similar trend in the association of TLR5 with
LD (SNP 1174T; OR   1.56 [95% CI   0.82, 2.98], SNP
1775G, OR   1.71 [95% CI   1.07, 2.72]). In addition,
there was no statistical association between any of the
TLR5 SNPs and diabetes (unpublished data).
Because smoking has previously been shown to be sig-
nificantly associated with LD, and this association was con-
firmed here, we investigated whether there was an inter-
action between smoking and TLR5 SNPs (Table IV;
Table III.  TLR5 SNP Allele and Haplotype Frequencies in Cases and Controls
SNP Cases
n   108
All controls
n   508
Matched controls
n   89
No.  BP Allele freq freq OR (95% CI) P freq OR (95% CI) P
1. 1174C 0 0.917  0.950  0.955
 1174T 1 0.083  0.050 1.75  (1.00,  3.05)   0.05  0.045 1.93 (0.74,  5.03)  0.18
2. 1775A 0 0.827 0.884 0.899
1775G 1 0.173 0.116 1.60  (1.04,  2.45) 0.03 0.101 1.83  (1.02,  3.28)  0.04
3. 1846T  0 0.520 0.520 0.540
1846C 1 0.480 0.480 1.00  (0.72,  1.38) 0.98  0.460 1.09  (0.71,  1.68)  0.70
Haplotype 1174-1775
CA 00 0.744 0.835 1 0.861 1
CG 01 0.173 0.115 1.68(1.10, 2.59) 0.02 0.094 2.11 (1.16, 3.85) 0.02
TA 10 0.083 0.049 1.90(1.07, 3.35) 0.03 0.038 2.53 (0.86, 7.49) 0.09
TG 11 0 0 0
0 represents the common allele at each locus; 1 is the uncommon allele. Haplotype alleles for SNP1 (1174) and SNP2 (1775) are listed in order. Odds
ratio (OR) and 95% confidence intervals represent a comparison of the cases with the two respective control groups with an unadjusted analysis.
Table IV.  Multivariate Analysis of Association of TLR5 SNPs 
with Legionnaires’ Disease in Smokers and Nonsmokers
SNP Smokers Nonsmokers
No. BP Allele OR (95% CI) P OR (95% CI) P
1. 1174C 0 1 1
1174T 1 0.72 (0.18, 2.86) 0.64 2.16 (0.89, 5.23) 0.09
2. 1775A 0 1 1
1775G 1 1.33 (0.54, 3.26) 0.54 1.84 (0.97, 3.48) 0.06
Haplotype 1174-1775
CA 00 1 1
CG 01 1.33 (0.55, 3.25) 0.53 1.99 (1.04, 3.80) 0.04
TA 10 0.76 (0.19, 3.05) 0.70 2.43 (1.00, 5.89) 0.05
Comparison is between cases (n   108) and the entire control group
(  508), excluding those with no information on smoking status. Odds
ratio (OR) and 95% confidence intervals were calculated by a
multivariate logistic regression analysis. All analyses are adjusted for
gender and age (stratified at  40, 40–49, 50–60, and 60 ), and then
ORs for smokers and nonsmokers were calculated separately through an
interaction term.T
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references 19, 30). The analysis revealed that the associa-
tion of 1174T-1775A and 1174C-1775G haplotypes with
LD was only found in the nonsmokers (ORs   2.43 [CI  
1.00, 5.89; P   0.05] and 1.99 [CI   1.04, 3.80; P  
0.04], respectively), whereas the association became mar-
ginal among smokers. This result implies that smoking may
be a dominant risk factor for LD and, thus, may mask ge-
netic associations. Together, these results suggest that
TLR5 SNPs are associated with LD in nonsmokers.
TLR5 Is the Predominant Mediator of IL-8 Expression in
Lung Epithelia.  These genetic findings raise the question
of why a deficiency in TLR5 would be deleterious to the
host because there are other PAMP receptors, including
TLR4, which could presumably still recognize L. pneumo-
phila and mediate an inflammatory response. To understand
TLR5 regulation of signaling in pulmonary epithelia, we
stimulated A549 lung cell lines and measured culture super-
natant IL-8 levels. As seen in previous analyses, LPS was un-
able to stimulate IL-8 production, even at doses of 1,000 ng
ml 1 (Fig. 3 A, not depicted) (31). In contrast, flagellin po-
tently stimulated IL-8 in a dose-dependent fashion, starting
at concentrations of 1 ng ml 1. Furthermore, although heat-
killed wild-type L. pneumophila induced IL-8 production, a
flagellin mutant strain (FlaA ) was nonstimulatory (Fig.
3 B). Similar results were obtained for IL-6 and IL-8 pro-
duction in Calu-3 lung epithelial cells (Fig. 3, C and D; and
not depicted). In contrast to epithelial cells, both wild-type
and FlaA  strains were similarly able to induce TNF- 
production in a whole blood cytokine assay (Fig. 3 E). This
control assay indicates that the FlaA  mutant did not have a
generalized loss of PAMPs that compromised its overall
stimulatory capacity. Overall, these results suggest a domi-
nant role for flagellin and TLR5 in regulating the pulmo-
nary epithelial innate immune response to L. pneumophila.
TLR5392STOP Has a Dominant Effect.  Because individu-
als who are heterozygous for the TLR5 stop codon are
more susceptible to LD, we examined whether
TLR5392STOP acts in a dominant fashion. We stimulated
PBMCs from individuals with flagellin or LPS and mea-
sured IL-6 cytokine production by ELISA. Heterozygous
stop codon individuals (392R*) had significantly decreased
IL-6 production in comparison to those with the wild-type
arginine at amino acid 392 (Fig. 3 F, 392RR; P   0.05).
In comparison, there was no difference in LPS-induced
IL-6 production (Fig. 3 G). This result indicates that
TLR5392STOP exerts a dominant effect and suggests that het-
erozygous TLR5 stop codon individuals are more suscepti-
ble to LD due to impaired production of proinflammatory
cytokines. We reanalyzed the genetic association of TLR5
C1174T with susceptibility to LD with the assumption that
TLR5392STOP exhibits a dominant effect. The genotype fre-
quency of 1174TC and TT (combined) was 16.7% in the
cases compared with 9.5% in the entire control group and
7.9% in the matched control group. The OR for the asso-
ciation of genotype 1174T (C,T) with developing LD was
1.90 (95% CI   1.06–3.42; P   0.03) when compared
with the entire group and 2.34 (95% CI   0.93–5.90; P  
0.07) in comparison to the matched control group. This
analysis confirmed and further strengthened the association
of TLR5392STOP with susceptibility to LD.
Discussion
In this paper, we show for the first time that a common
TLR5 stop codon polymorphism acts in a dominant fash-
ion and is associated with susceptibility to infection with a
flagellated organism in humans. We further show that
TLR5–flagellin interactions control IL-8 production in
lung epithelial cell lines stimulated by L. pneumophila.
Although these results suggest an association of TLR5
with LD, we cannot exclude that these SNPs are in linkage
Figure 3. FliC stimulation of cytokine production. (A–E) Cells were
stimulated with LPS ( ), purified S. typhimurium FliC ( ), heat-killed
wild-type L. pneumophila ( ), or FlaA  (FliC mutant) L. pneumophila
( ). (A and B) A549 cells; (C and D) Calu-3 cells; and (E) whole blood.
(F–G) PBMCs were harvested from individuals with homozygous wild-
type TLR5 (392RR; n   6) or stop codon TLR5 heterozygotes (392R*;
n   4). Cells were stimulated with FliC at 30 ng/ml 1 (F) or LPS at 10
ng/ml 1 (G). (A–G) Cells were stimulated for 18 h and supernatants were
assayed for cytokine production by ELISA. Data are representative of
experiments performed at least twice in triplicate with standard deviations
indicated. (F and G) The mean level and standard deviation of IL-6 were
derived from averaging the responses of different individual’s cells stimu-
lated in triplicate.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
TLR5 and Legionella pneumophila 1570
disequilibrium with a nearby causative gene or that there is
a confounding effect from population admixture. The latter
possibility is unlikely given that the entire cohort was
Dutch with  95% of both cases and controls being Cauca-
sian Dutch. In addition, the matched control group
showed similar trends of association. This control group in-
cluded place of residence as a matching variable as a strat-
egy to control for more subtle influences of population
stratification. The association of the stop codon SNP with
LD is more striking given that this is almost exclusively a
heterozygous population. Furthermore, no DNA was
available from the 18 individuals with LD who died, a
group with an increased probability of having a susceptible
genetic profile.
Previous works have found a number of risk factors for
acquiring LD, including age, smoking, chronic lung dis-
ease, cancer, and immunosuppression (19, 27, 30, 32). This
is the first study with evidence that supports a genetic basis
for susceptibility to LD. In fact, association of SNPs with
susceptibility to bacterial pneumonia has only been linked
to a small number of genes, including mannose binding
lectin and FcRIIa (33, 34). Our analytic approach high-
lights the importance of separating the effects of genetic
and environmental variables on disease outcome because
the genetic association of TLR5 with LD was exclusive to
the nonsmoking population.
Our finding that flagellin is the major L. pneumophila
stimulant of IL-8 production in lung epithelial cell lines has
important implications for models of innate immunity.
Previous investigators have demonstrated that the A549
lung epithelial cell line does not respond to LPS, even at
doses of 1  g ml 1 (31, 35). Normal lung epithelia may
down-regulate LPS recognition through TLR4 as a protec-
tive mechanism to avoid an overly exuberant inflammatory
response (36). A previous paper found that Pseudomonas
flagellin, but not LPS, stimulated IL-8 production in tra-
cheal epithelial cells (37). Several recent works with intesti-
nal and lung epithelial cells also demonstrate that flagellin is
a major stimulus of proinflammatory cytokine production
(38–44). Together, these results suggest that PAMP recog-
nition in epithelial cells is more constrained than macro-
phages and may explain why a selective TLR5 deficiency
can predispose an individual to an increased risk of pneu-
monia due to a flagellated organism.
If there is redundancy in the innate immune system,
there may be no detriment to having a stop codon in
TLR5 if an individual has a wild-type version of TLR4.
However, there are several reasons why TLR4 is unlikely
to easily replace the function of TLR5. First, lung epithelial
cell lines recognize LPS poorly and suggest that there are
cell and organ-specific differences in TLR regulation and
function. Second, L. pneumophila LPS is  1000-fold less
stimulatory than S. typhimurium LPS (45–47). With such
low stimulatory properties, L. pneumophila LPS may not be
a major target of innate immune system recognition. Third,
we have shown previously that TLR4-defective mice are
not more susceptible to aerosolized infection with L. pneu-
mophila (48). In addition, we found that TLR4 is not in-
volved with recognition of heat-killed L. pneumophila by
murine macrophages. These studies suggest that receptors
other than TLR4 mediate recognition of L. pneumophila
during an in vivo infection. Finally, even if TLR4 mediates
L. pneumophila recognition, there may be qualitative or
quantitative differences in the TLR4 induced gene expres-
sion profiles in comparison to TLR5 stimulation.
Although the importance of TLRs in regulating the in-
nate immune response has been clearly demonstrated in an-
imal models, the clinical significance of TLR polymor-
phisms in human disease susceptibility is only beginning to
be elucidated. Recent analyses with TLR4 SNPs suggest a
PAMP-specific influence of this gene on infectious disease
susceptibility because TLR4 is associated with gram-nega-
tive bacterial infections (7, 8, 10, 11). The finding that
TLR5 SNPs are associated with susceptibility to a flagel-
lated bacterium supports the hypothesis that susceptibility
profiles will be PAMP-dependent and vary between infec-
tions. The high frequency of the TLR5 stop codon muta-
tion in apparently healthy individuals raises the question of
whether there is an evolutionary advantage to having this
genetic variant. Linkage papers have mapped a major sus-
ceptibility locus for systemic lupus erythematosus in hu-
mans and mice to chromosome 1q41 where TLR5 resides
(49, 50). Given TLR5’s role in mediating inflammatory
signaling pathways, it will be of interest to examine its pos-
sible association with an autoimmune disease such as sys-
temic lupus erythematosus.
The dominant effect of the stop codon mutation implies
that  10% of individuals have severely impaired ability to
recognize flagellated bacteria and may be more susceptible
to infection. The presence of the stop codon in the extra-
cellular ligand-binding domain, in contrast to the intracel-
lular signaling domain, suggests that the dominant effect
occurs through a unique mechanism. Because TLR5 acts
as a homodimer, the stop codon variant may bind to the
normal variant and inhibit its proper assembly or localiza-
tion. Understanding this unusual mechanism may lead to
novel insights for immunomodulatory treatment of inflam-
matory diseases.
We thank H.C. Boshuizen for establishing the database for con-
trols, and A. Siegel and N. Khalid for statistical insights. 
This work was supported by the National Institutes of Health
grants to T.R. Hawn, K. Smith, L.P. Zhao, and A. Aderem. A
Postdoctoral Physician Fellowship from the Howard Hughes Med-
ical Institute supported T.R. Hawn.
Submitted: 22 July 2003
Accepted: 6 October 2003
References
1. Bartlett, J.G., and L.M. Mundy. 1995. Community-acquired
pneumonia. N. Engl. J. Med. 333:1618–1624.
2. Cooke, G.S., and A.V. Hill. 2001. Genetics of susceptibility
to human infectious disease. Nat. Rev. Genet. 2:967–977.
3. Aderem, A., and R.J. Ulevitch. 2000. Toll-like receptors inT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Hawn et al. 1571
the induction of the innate immune response. Nature. 406:
782–787.
4. Janeway, C.A., Jr., and R. Medzhitov. 2002. Innate immune
recognition. Annu. Rev. Immunol. 20:197–216.
5. Poltorak, A., X. He, I. Smirnova, M.Y. Liu, C.V. Huffel, X.
Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998.
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr
mice: mutations in Tlr4 gene. Science. 282:2085–2088.
6. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like recep-
tors. Annu. Rev. Immunol. 21:335–376.
7. Lorenz, E., J.P. Mira, K.L. Frees, and D.A. Schwartz. 2002.
Relevance of mutations in the TLR4 receptor in patients
with gram-negative septic shock. Arch. Intern. Med. 162:
1028–1032.
8. Agnese, D.M., J.E. Calvano, S.J. Hahm, S.M. Coyle, S.A.
Corbett, S.E. Calvano, and S.F. Lowry. 2002. Human Toll-
like receptor 4 mutations but not CD14 polymorphisms are
associated with an increased risk of gram-negative infections.
J. Infect. Dis. 186:1522–1525.
9. Arbour, N., E. Lorenz, B. Schutte, J. Zabner, J. Kline, M.
Jones, K. Frees, J. Watt, and D. Schwartz. 2000. TLR4 mu-
tations are associated with endotoxin hyporesponsiveness in
humans. Nat Gen. 25:187–191.
10. Kiechl, S., E. Lorenz, M. Reindl, C.J. Wiedermann, F.
Oberhollenzer, E. Bonora, J. Willeit, and D.A. Schwartz.
2002. Toll-like receptor 4 polymorphisms and atherogenesis.
N. Engl. J. Med. 347:185–192.
11. Smirnova, I., N. Mann, A. Dols, H.H. Derkx, M.L. Hibberd,
M. Levin, and B. Beutler. 2003. Assay of locus-specific ge-
netic load implicates rare Toll-like receptor 4 mutations in
meningococcal susceptibility. Proc. Natl. Acad. Sci. USA. 100:
6075–6080.
12. Hayashi, F., K.D. Smith, A. Ozinsky, T.R. Hawn, E.C. Yi,
D.R. Goodlett, J.K. Eng, S. Akira, D.M. Underhill, and A.
Aderem. 2001. The innate immune response to bacterial
flagellin is mediated by Toll-like receptor 5. Nature. 410:
1099–1103.
13. Smith, K.D., and A. Ozinsky. 2002. Toll-like receptor-5 and
the innate immune response to bacterial flagellin. Curr. Top.
Microbiol. Immunol. 270:93–108.
14. Ibrahim, G.F., G.H. Fleet, M.J. Lyons, and R.A. Walker.
1985. Method for the isolation of highly purified Salmonella
flagellins. J. Clin. Microbiol. 22:1040–1044.
15. Kawai, T., O. Adachi, T. Ogawa, K. Takeda, and S. Akira.
1999. Unresponsiveness of Myd88-deficient mice to endo-
toxin. Immunity. 11:115–122.
16. Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa,
Y. Takeda, K. Takeda, and S. Akira. 1999. Cutting edge:
toll-like receptor 4 (TLR4)-deficient mice are hyporespon-
sive to lipopolysaccharide: evidence for TLR4 as the Lps
gene product. J. Immunol. 162:3749–3752.
17. Heuner, K., L. Bender-Beck, B.C. Brand, P.C. Luck, K.H.
Mann, R. Marre, M. Ott, and J. Hacker. 1995. Cloning and
genetic characterization of the flagellum subunit gene (flaA)
of Legionella pneumophila serogroup 1. Infect. Immun. 63:2499–
2507.
18. Sadosky, A.B., L.A. Wiater, and H.A. Shuman. 1993. Identi-
fication of Legionella pneumophila genes required for growth
within and killing of human macrophages. Infect. Immun. 61:
5361–5373.
19. Den Boer, J.W., E.P. Yzerman, J. Schellekens, K.D. Lettinga,
H.C. Boshuizen, J.E. Van Steenbergen, A. Bosman, S. Van
den Hof, H.A. Van Vliet, M.F. Peeters, et al. 2002. A large
outbreak of Legionnaires’ disease at a flower show, the Neth-
erlands, 1999. Emerg. Infect. Dis. 8:37–43.
20. Boshuizen, H.C., S.E. Neppelenbroek, H. van Vliet, J.F.
Schellekens, J.W. den Boer, M.F. Peeters, and M.A. Conyn-
van Spaendonck. 2001. Subclinical Legionella infection in
workers near the source of a large outbreak of Legionnaires’
disease. J. Infect. Dis. 184:515–518.
21. Lettinga, K.D., A. Verbon, G.J. Weverling, J.F. Schellekens,
J.W. Den Boer, E.P. Yzerman, J. Prins, W.G. Boersma, R.J.
Van Ketel, J.M. Prins, and P. Speelman. 2002. Legionnaires’
disease at a dutch flower show: prognostic factors and impact
of therapy. Emerg. Infect. Dis. 8:1448–1454.
22. Li, S.S., N. Khalid, C. Carlson, and L.P. Zhao. 2003. Esti-
mating haplotype frequencies and standard errors for multiple
single nucleotide polymorphisms. Biostatistics. 4:513–522.
23. Zhao, L.P., S.S. Li, and N. Khalid. 2003. A method for the
assessment of disease associations with single-nucleotide poly-
morphism haplotypes and environmental variables in case-
control studies. Am. J. Hum. Gen. 72:1231–1250.
24. Gordon, D., C. Abajian, and P. Green. 1998. Consed: a
graphical tool for sequence finishing. Genome Res. 8:195–
202.
25. Hajjar, A.M., D.S. O’Mahony, A. Ozinsky, D.M. Underhill,
A. Aderem, S.J. Klebanoff, and C.B. Wilson. 2001. Cutting
edge: functional interactions between toll-like receptor
(TLR) 2 and TLR1 or TLR6 in response to phenol-soluble
modulin. J. Immunol. 166:15–19.
26. Swanson, M.S., and B.K. Hammer. 2000. Legionella pneumo-
phila pathogesesis: a fateful journey from amoebae to macro-
phages. Annu. Rev. Microbiol. 54:567–613.
27. Stout, J.E., and V.L. Yu. 1997. Legionellosis. N. Engl. J. Med.
337:682–687.
28. Roig, J., C. Domingo, and J. Morera. 1994. Legionnaires’
disease. Chest. 105:1817–1825.
29. Reingold, A.L. 1988. Role of legionellae in acute infections
of the lower respiratory tract. Rev. Infect. Dis. 10:1018–1028.
30. Fraser, D.W., T.R. Tsai, W. Orenstein, W.E. Parkin, H.J.
Beecham, R.G. Sharrar, J. Harris, G.F. Mallison, S.M. Mar-
tin, J.E. McDade, et al. 1977. Legionnaires’ disease: descrip-
tion of an epidemic of pneumonia. N. Engl. J. Med. 297:
1189–1197.
31. Pugin, J., C.C. Schurer-Maly, D. Leturcq, A. Moriarty, R.J.
Ulevitch, and P.S. Tobias. 1993. Lipopolysaccharide activa-
tion of human endothelial and epithelial cells is mediated by
lipopolysaccharide-binding protein and soluble CD14. Proc.
Natl. Acad. Sci. USA. 90:2744–2748.
32. Marston, B.J., H.B. Lipman, and R.F. Breiman. 1994. Sur-
veillance for Legionnaires’ disease. Risk factors for morbidity
and mortality. Arch. Intern. Med. 154:2417–2422.
33. Yee, A.M., H.M. Phan, R. Zuniga, J.E. Salmon, and D.M.
Musher. 2000. Association between FcgammaRIIa-R131 al-
lotype and bacteremic pneumococcal pneumonia. Clin. Infect.
Dis. 30:25–28.
34. Roy, S., K. Knox, S. Segal, D. Griffiths, C.E. Moore, K.I.
Welsh, A. Smarason, N.P. Day, W.L. McPheat, D.W.
Crook, and A.V. Hill. 2002. MBL genotype and risk of inva-
sive pneumococcal disease: a case-control study. Lancet. 359:
1569–1573.
35. Standiford, T.J., S.L. Kunkel, M.A. Basha, S.W. Chensue,
J.P. Lynch, III, G.B. Toews, J. Westwick, and R.M. Strieter.
1990. Interleukin-8 gene expression by a pulmonary epithe-
lial cell line. A model for cytokine networks in the lung. J.
Clin. Invest. 86:1945–1953.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
TLR5 and Legionella pneumophila 1572
36. Martin, T.R. 2000. Recognition of bacterial endotoxin in
the lungs. Am. J. Respir. Cell Mol. Biol. 23:128–132.
37. DiMango, E., H.J. Zar, R. Bryan, and A. Prince. 1995. Di-
verse Pseudomonas aeruginosa gene products stimulate respi-
ratory epithelial cells to produce interleukin-8. J. Clin. Invest.
96:2204–2210.
38. Steiner, T.S., J.P. Nataro, C.E. Poteet-Smith, J.A. Smith, and
R.L. Guerrant. 2000. Enteroaggregative Escherichia coli ex-
presses a novel flagellin that causes IL-8 release from intestinal
epithelial cells. J. Clin. Invest. 105:1769–1777.
39. Reed, K.A., M.E. Hobert, C.E. Kolenda, K.A. Sands, M.
Rathman, M. O’Connor, S. Lyons, A.T. Gewirtz, P.J. San-
sonetti, and J.L. Madara. 2002. The Salmonella typhimurium
flagellar basal body protein FliE is required for flagellin pro-
duction and to induce a proinflammatory response in epithe-
lial cells. J. Biol. Chem. 277:13346–13353.
40. Sierro, F., B. Dubois, A. Coste, D. Kaiserlian, J.P. Kraehen-
buhl, and J.C. Sirard. 2001. Flagellin stimulation of intestinal
epithelial cells triggers CCL20-mediated migration of den-
dritic cells. Proc. Natl. Acad. Sci. USA. 98:13722–13727.
41. Liaudet, L., C. Szabo, O.V. Evgenov, K.G. Murthy, P.
Pacher, L. Virag, J.G. Mabley, A. Marton, F.G. Soriano,
M.Y. Kirov, et al. 2003. Flagellin from gram-negative bacte-
ria is a potent mediator of acute pulmonary inflammation in
sepsis. Shock. 19:131–137.
42. Gewirtz, A.T., P.O. Simon, Jr., C.K. Schmitt, L.J. Taylor,
C.H. Hagedorn, A.D. O’Brien, A.S. Neish, and J.L. Madara.
2001. Salmonella typhimurium translocates flagellin across intes-
tinal epithelia, inducing a proinflammatory response. J. Clin.
Invest. 107:99–109.
43. Gewirtz, A.T., T.A. Navas, S. Lyons, P.J. Godowski, and J.L.
Madara. 2001. Cutting edge: bacterial flagellin activates baso-
laterally expressed TLR5 to induce epithelial proinflamma-
tory gene expression. J. Immunol. 167:1882–1885.
44. Eaves-Pyles, T., K. Murthy, L. Liaudet, L. Virag, G. Ross,
F.G. Soriano, C. Szabo, and A.L. Salzman. 2001. Flagellin, a
novel mediator of Salmonella-induced epithelial activation
and systemic inflammation: I kappa B alpha degradation, in-
duction of nitric oxide synthase, induction of proinflamma-
tory mediators, and cardiovascular dysfunction. J. Immunol.
166:1248–1260.
45. Zahringer, U., Y.A. Knirel, B. Lindner, J.H. Helbig, A. Son-
esson, R. Marre, and E.T. Rietschel. 1995. The lipopolysac-
charide of Legionella pneumophila serogroup 1 (strain Philadel-
phia 1): chemical structure and biological significance. Prog.
Clin. Biol. Res. 392:113–139.
46. Wong, K.H., C.W. Moss, D.H. Hochstein, R.J. Arko, and
W.O. Schalla. 1979. “Endotoxicity” of the Legionnaires’ dis-
ease bacterium. Ann. Intern. Med. 90:624–627.
47. Neumeister, B., M. Faigle, M. Sommer, U. Zahringer, F.
Stelter, R. Menzel, C. Schutt, and H. Northoff. 1998. Low
endotoxic potential of Legionella pneumophila lipopolysaccha-
ride due to failure of interaction with the monocyte li-
popolysaccharide receptor CD14. Infect. Immun. 66:4151–
4157.
48. Lettinga, K.D., S. Florquin, P. Speelman, R. van Ketel, T.
van der Poll, and A. Verbon. 2002. Toll-like receptor 4 is not
involved in host defense against pulmonary Legionella pneumo-
phila infection in a mouse model. J. Infect. Dis. 186:570–573.
49. Tsao, B.P., R.M. Cantor, K.C. Kalunian, C.J. Chen, H.
Badsha, R. Singh, D.J. Wallace, R.C. Kitridou, S.L. Chen,
N. Shen, et al. 1997. Evidence for linkage of a candidate
chromosome 1 region to human systemic lupus erythemato-
sus. J. Clin. Invest. 99:725–731.
50. Wakeland, E.K., K. Liu, R.R. Graham, and T.W. Behrens.
2001. Delineating the genetic basis of systemic lupus erythe-
matosus. Immunity. 15:397–408.